Newsroom

Announcements

  • 03 August 2020

    Jubilant Life Sciences Limited announces launch of ‘JUBI-R’ (remdesivir) in India for the treatment of COVID-19

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited (“Jubilant”), has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection).

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited (“Jubilant”), has launched remdesivir for injection under the brand name ‘JUBI-R’ in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection). The Company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network. Jubilant’s 24 hour help line will enhance access to ‘JUBI-R’ during these pandemic times, where timely access to the drug may prove critical to treatment outcomes.

    In order to increase accessibility of ‘JUBI-R’ to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at distribution of the drug.

    In May 2020, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (NASDAQ: GILD) that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries including India. Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the USFDA for treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalized with severe disease. On July 20, 2020, Jubilant received approval from the Drug Controller General of India (DCGI) to manufacture and market the investigational antiviral drug remdesivir (“JUBI-R”) for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19. ‘JUBI-R’ will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.

    “It gives us immense satisfaction to launch ‘JUBI-R’ as this drug has a potential to save precious lives across the globe. We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet high demand for the drug in the Indian market and in other countries,” stated Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences Limited. “The Company’s ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions. Through the Jubilant Bhartia Foundation, we will distribute the drug on compassionate basis to save precious lives of people through unique programs.”

  • 28 July 2020

    JUBILANT BIOSYS LIMITED announces the merger with JUBILANT CHEMSYS LIMITED

    Jubilant Biosys Limited (“Biosys”), a wholly owned subsidiary of Jubilant Life Sciences Limited, today announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India. The combined entities will now operate as Jubilant Biosys Limited.

    Jubilant Biosys Limited (“Biosys”), a wholly owned subsidiary of Jubilant Life Sciences Limited, today announced completion of the merger with its sister company Jubilant Chemsys Limited, based in Noida, India. The combined entities will now operate as Jubilant Biosys Limited.

    The merger will simplify operations and provide customers with a single brand access for a wide range of discovery, IND and PR&D and GMP development services. Biosys had earlier announced significant investment in building new state-of-the-art research facilities in Greater Noida and in Bengaluru, India to cater to increasing customer demand for its functional services (medicinal & synthetic chemistry, structural biology, DMPK, Biology & GMP scale-up) and notably integrated drug discovery services.

    Marcel Velterop, President- Jubilant Biosys Limited and CDMO, said: “We are delighted to make this merger happen and focus our investments for growth to expand both the chemistry as well as integrated drug discovery capabilities. It provides clarity to customers and enables us to better deliver on our “4D” promise of accelerating the discovery process through increased digitization of our operations and information flow.”

    About Jubilant Biosys Limited:

    Jubilant Biosys, a Bengaluru based wholly owned subsidiary of Jubilant Life Sciences Ltd, offers contract research & development services for global pharmaceutical innovators. Biosys has demonstrated expertise in functional services such as Biology, DMPK, Toxicology as well as Medicinal Chemistry, PR&D and GMP scale-up capabilities up to phase II. It has a proven track record of delivering over 75 integrated programs in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation, CNS and expanding into Rare Diseases. Its sister company, TrialStat Solution Inc., provides an advanced EDC platform to accelerate clinical trials’ data capture and processing. For more info, please visit www.jubilantbiosys.com.

  • 20 July 2020

    Jubilant Life Sciences Limited announces approval of ‘JUBI-R’ (remdesivir) in India for the treatment of COVID-19

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited (“Jubilant”), has received approval from the Drug Controller General of India (DCGI) to manufacture

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited (“Jubilant”), has received approval from the Drug Controller General of India (DCGI) to manufacture and market the investigational antiviral drug remdesivir for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19.
    Jubilant’s remdesivir product will be marketed under the brand name ‘JUBI-R’ in India and will be made available in 100 mg vials (injectable). It would be administered intravenously in a hospital setting under the supervision of a medical practitioner. The Company will distribute the drug in the Indian market through its distribution network and will be available by the first week of August 2020.

    In May 2020, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (NASDAQ: GILD) that granted it the right to register, manufacture and sell Gilead’s investigational drug remdesivir in 127 countries including India. Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the USFDA for treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalized with severe disease.

    “We are very pleased to launch ‘JUBI-R’, a drug with potential to save lives of people who have contracted COVID-19,” stated Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences Limited.  “At Jubilant, we are focused on quickly making this drug available in India in required quantities and at affordable prices. This milestone underscores our continued commitment to provide leading healthcare solutions as well as demonstrates our ability to leverage our broad capabilities to deliver important new medicines.”

  • 22 June 2020

    Jubilant Therapeutics Presents Preclinical Data at the American Association for Cancer Research, Reveals Unique Dual-Action Anti-Cancer Mechanism Underscoring First-in-Class Pipeline Asset in Hematological Tumors

    -- Findings indicate JBI-802 is a potent and selective oral dual inhibitor of LSD1 and HDAC6 with enhanced anti-tumor activity in hematological cancer and favorable safety profile.

    BEDMINSTER, NJ -- June 22, 2020 – Jubilant Therapeutics Inc., a biopharmaceutical company advancing small molecule modulators to address unmet medical needs in oncology and autoimmune diseases, today announced that preclinical data  of dual LSD1 and HDAC6 inhibitor JBI-802, will be presented in a poster session at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The preclinical data demonstrated that JBI-802 has strong efficacy in multiple in vivo cancer models mediated by LSD1 and HDAC6 inhibition, while demonstrating excellent selectivity against other HDACs and superior in vivo efficacy compared to single agents targeting LSD1 or HDAC6.

    “We are excited to reveal these new data from our study of JBI-802 whose first-in-class dual mechanism of action targets the overexpression of two proteins, while exhibiting a favorable tolerability profile,” said Syed Kazmi, President and Chief Executive Officer of Jubilant Therapeutics Inc. “These data support the additional development of this novel dual epigenetic inhibitor as a potential therapeutic agent for genetically-defined cancers.”

    A link to the e-poster, listed below, is available through the AACR website.

    Title: Novel Dual Small Molecule Inhibitor Targeting LSD1 and HDAC6
    Poster Number: 1756
    Date and Time: June 22, 2020 at 8:45 a.m. Eastern Daylight Time (EDT)
    Session Title: Epigenetic Targets
    Presenter: Dhanalakshmi Sivanandhan, et al.

    Key highlights from the study which examined anti-proliferative activity of JBI-802 on select acute myeloid leukemia (AML), chronic lymphocytic leukemia, small cell lung cancer, sarcoma and multiple myeloma cell lines as compared to single agents, include the following:

    • JBI-802 demonstrated strong tumor growth inhibition in erythroleukemia and multiple other hematological tumors as compared to single agents;
    • Syngeneic models showed single agent activity with unique mechanism of action and that JBI-802 can be combined with checkpoint inhibitors safely in this mouse model; and
    • The molecule showed a favorable tolerability profile at efficacious doses.

    JBI-802 is currently being evaluated in IND-enabling studies for the treatment of AML and other solid tumors and first-in-human clinical studies are expected in 1H 2021. Jubilant Therapeutics Inc. is developing a pipeline of novel, differentiated therapeutic assets; for partnership opportunity inquiries please contact BD@jubilanttx.com.

    About Jubilant Therapeutics Inc.

    Jubilant Therapeutics Inc. is a patient-centric biopharmaceutical company advancing potent and selective small molecule modulators to address unmet medical needs in oncology and autoimmune diseases. Our advanced discovery engine integrates structure-based design and computational algorithms to discover and develop novel, precision therapeutics against both first-in-class and validated but intractable targets in genetically-defined patient populations. The company’s entrepreneurial-minded leadership and scientific teams strive for speed and efficiency by employing a business model that leverages the proven and synergistic capabilities of Jubilant Life Sciences’ value chain and shared services. Jubilant Therapeutics is headquartered in the U.S. and guided by globally renowned key opinion leaders and scientific advisory board members.

    Media Contacts
    MacDougall
    Amanda Whelan or Susan Sharpe
    awhelan@macbiocom.com or ssharpe@macbiocom.com
    (781) 235-3060

    Link: Click here

  • 29 May 2020

    JUBILANT LIFE SCIENCES – Q4 & FY20 RESULTS

    The Board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company met today to approve financial results for the quarter ended March 31, 2020.

    • FY20 Revenue at Rs 9,154 Crore; Q4’FY20 Revenue at Rs 2,391 Crore
    • FY20 EBITDA at Rs 1,995 Crore up 12% YoY; Q4’FY20 EBITDA at Rs 556 Crore up 58% YoY

    The Board of Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company met today to approve financial results for the quarter ended March 31, 2020.

    Commenting on the Company’s performance, Mr. Shyam S Bhartia, Chairman and Mr. Hari S Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences said:
    “We are glad to report record profits in FY20 with improvement in margins across all the business segments. The Q4FY20 performance was impressive with EBITDA growth of 58% YoY. Despite the Covid-19 led challenges, we continue to experience strong demand across most of our businesses. Our leadership position in all the segments we operate in ensures positive outlook for business performance and healthy cashflow generation to reduce leverage.”

    Pharmaceutical segment recorded revenue of Rs 5,714 Crore during FY20 as against Rs 5,349 Crore in FY19. The 7% YoY revenue growth during the year was driven by better performance in all three key business lines. EBITDA was at Rs 1,555 Crore, up 13% YoY with margin at 27.2%, as compared with 25.7% in FY19.

    LSI segment’s FY20 revenue was at Rs 3,179 Crore as against Rs 3,545 Crore last year. LSI’s FY20 EBITDA was at Rs 431 Crore vs. Rs 445 Crore last year with margin at 13.6% vs. 12.6% last year.

    The Drug Discovery Services business’ FY20 revenue increased to Rs 262 Crore from Rs 217 Crore with 28.1% EBITDA margin in the current year as against 8.3% EBITDA margin in FY19. In view of the strong demand, we are making investments in this business to double capacities over the next 2-3 years.

    In our Proprietary Drug Discovery business, we are working on more than six programs targeting small molecule therapies in the area of oncology and auto-immune disorders with two programs moving to the clinic next year.

    During the year, the company reduced its Net Debt by Rs 514 Crore and is focused on further deleveraging by generating healthy levels of cashflows.

    Company signed Licensing Agreement with Gilead Sciences to register, manufacture and sell Gilead’s investigational drug, remdesivir, a potential therapy for Covid-19 in 127 countries including India, and is working towards launching the drug in July 2020.

    The Company has taken several measures to tide over the COVID-19 induced challenges. We are confident of delivering sustained growth in the medium term on the back of our leadership position in various businesses and growth strategies.
    Q4’FY20 Highlights

    Consolidated

    • Revenue at Rs 2,391 Crore, as compared with Rs 2,386 Crore in Q4’FY19
    • EBITDA at Rs 556 Crore increased 58% YoY and 8% sequentially. EBITDA margin at 23.3% vs. 14.7% in Q4’FY19 and 22.2% in Q3’FY20
    • Adjusted EBITDA after one-off expenses at Rs 568 Crore up 46% YoY from Rs 388 Crore in Q4’FY19. Adjusted EBITDA margin for the quarter was 23.7% vs. 16.3% in Q4’FY19
    • Finance costs at Rs 71 Crore vs. Rs 62 Crore in Q4’FY19 and Rs 72 Crore in Q3’FY20
    • Net Profit at Rs 260 Crore as compared with Rs (99) Crore in Q4’FY20. EPS of Rs 16.4 vs. Rs (6.4) in Q4’FY19
      • Q4’FY19 had an Exceptional charge of Rs 235 Crore related to settlement of IFC convertible loan
    • Normalised PAT at Rs. 260 Crore vs. Rs 135 Crore in Q4’FY19. Normalised EPS at Rs. 16.4 vs. Rs 8.5 in Q4’FY19
    • Capex in Q4’FY20 of Rs 89 Crore
    • Net debt on a constant currency basis lower by Rs 297 Crore during Q4’FY20
    • In Q4’FY20, Company announced and paid an Interim Dividend @ 500% i.e. Rs. 5 per share of Rs 1 paid up for FY20, which is the Final dividend for the year as well

     

    Segment Wise Analysis

    Pharmaceuticals Segment

    • Pharmaceuticals revenue at Rs 1,483 Crore, an increase of 6% YoY and 2% QoQ. Specialty Pharma and Generics segments increased by 13% YoY and 17% YoY, respectively. CDMO revenue decreased 13% YoY due to Covid-19 related disruption at the API plant in March
    • Pharmaceuticals EBITDA at Rs 429 Crore, an increase of 50% YoY with margin of 28.9% as compared to 20.3% in Q4’FY19 and 28.4% in Q3’FY20
    • Pharmaceuticals adjusted EBITDA at Rs 440 Crore increased by 37% YoY with a margin of 29.7% as compared to 22.9% in Q4’FY19
    • R&D spent during the quarter of Rs. 42 Crore – 2.9% to segment sales. R&D debited to P&L is Rs. 43 Crore – 2.9% to segment sales
    • During the quarter, the Company transferred the India Branded Pharmaceuticals business to its indirect subsidiary, Jubilant Generics Limited.

    Life Science Ingredients Segment

    • LSI revenue in Q4FY20 at Rs 823 Crore compared to Rs 912 Crore in Q4FY19
    • EBITDA at Rs 118 Crore increased by 17% YoY and 18% QoQ with margin of 14.4% as compared to 11% in Q4’FY19

     

    Drug Discovery & Development Solutions1 Segment

    • DDDS revenue increased by 25% YoY to Rs 85 Crore led by growth in Drug Discovery Services business
    • EBITDA at Rs 35 Crore as compared to Rs (1) Crore in Q4’FY19 with margin improved to 40.7% from (1.1)% in Q4’FY19.
    • Drug Discovery & Development Solutions include the Drug Discovery Services (Jubilant Biosys & Jubilant Chemsys) business and Proprietary Drug Discovery business (Jubilant Therapeutics)

     

    FY20 Highlights

    Consolidated

    • Revenue at Rs 9,154 Crore up from Rs 9,111 Crore in FY19
    • Reported EBITDA at Rs 1,995 Crore increased by 12% YoY. EBITDA margin at 21.8% against 19.5% in FY19, an increase of 231 bps
    • Adjusted EBITDA after one-off expenses at Rs 2,066 Crore vs. Rs 1,860 Crore in FY19, growth of 11% YoY. Adjusted EBITDA margin in FY20 was 22.6% vs. 20.4% in FY19
    • Finance costs at Rs 287 Crore as compared to Rs 220 Crore in FY19.
    • Net Profit at Rs 898 Crore up 56% YoY. EPS of Rs 56.4 vs. Rs 36.9 in FY19
      • FY20 exceptional charge of Rs 35 Crore was related to Rs 23.3 Crore charge for prepayment of high yield bonds and NCDs and Rs 11.3 Crore related to asset write-off. FY19 exceptional charge of Rs 280 Crore was related to settlement of IFC convertible loan
    • Normalised PAT at Rs. 933 Crore vs. Rs 855 Crore in FY19. Normalised EPS at Rs. 58.6 vs. Rs 53.7 in FY19
    • Capex in FY20 of Rs 516 Crore
    • Net debt lower by Rs 514 Crore during FY20

     

    Segment Wise Analysis

    Pharmaceuticals Segment

    • Revenue at Rs 5,714 Crore, increased by 7% YoY, led by growth in all three revenue segments with 7% growth in Specialty Pharma, 5% growth in CDMO and 10% growth in Generics
    • EBITDA at Rs  1,555 Crore up 13% YoY with a margin of 27.2% as compared to 25.7% in FY19
    • Adjusted EBITDA at Rs  1,619 Crore increased 11% YoY with a margin of 28.3% as compared to 27.2% in FY19
    • R&D spent during FY20 at Rs. 228 Crore – 4% to segment sales. R&D debited to P&L is Rs. 199 Crore – 3.5% to segment sales

    Life Science Ingredients Segment

    • LSI revenue at Rs 3,179 Crore vs Rs 3,545 crore during FY19. Strong growth witnessed in Specialty Intermediates and Nutritional Products
    • EBITDA at Rs 431 Crore with margin of 13.6% as compared to 12.6% in FY19.
    • Adjusted EBITDA at Rs 440 Crore, with a margin of 13.8% as compared to 12.6% in FY19

    Drug Discovery & Development Solutions Segment

      • DDDS segment revenue increased 21% YoY to Rs 262 Crore
      • EBITDA increased by over three times to Rs 73 Crore from Rs 18 Crore FY19; FY20 margin at 28.1% up from 8.3% in FY19
  • 12 May 2020

    Jubilant Life Sciences Limited enters into Licensing Agreement with Gilead for Remdesivir, a potential therapy for Covid-19

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited.

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, is pleased to announce that its subsidiary, Jubilant Generics Limited (“Jubilant”), has entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. (NASDAQ: GILD) that will grant Jubilant the right to register, manufacture and sell Gilead’s investigational drug, remdesivir, a potential therapy for Covid-19 in 127 countries including India. These countries consist of nearly all low-income and lower middle-income countries, as well as several upper-middle and high-income countries that face significant obstacles to healthcare access. Under the licensing agreement, Jubilant will have the right to receive a technology transfer of the Gilead manufacturing process to scale up production to enable expedited access of the medicine to Covid-19 patients upon approvals by regulatory authorities in respective countries.

    Commenting on the partnership, Mr. Shyam S. Bhartia, Chairman and Mr. Hari S. Bhartia, Co-Chairman & Managing Director, Jubilant Life Sciences Limited, said, “We are very happy to strengthen our partnership with Gilead to license remdesivir, which, based on initial data, shows promise to be a potential therapy for Covid-19, a pandemic creating unprecedented health and economic crisis globally. We will be monitoring the clinical trials and regulatory approvals very closely and would be ready to launch the drug shortly after the required regulatory approvals. We also plan to produce the drug’s Active Pharmaceutical Ingredient (“API”) in-house helping its cost effectiveness and consistent availability.”

    Remdesivir, an investigational antiviral therapy developed by Gilead, received Emergency Use Authorization (EUA) by USFDA to treat Covid-19. The EUA will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease. The EUA is based on available data from two global clinical trials – US National Institute for Allergy and Infectious Diseases’ placebo-controlled Phase 3 study in patients with moderate to severe symptoms of COVID-19, and Gilead’s global Phase 3 study evaluating remdesivir in patients with severe disease. Multiple additional clinical trials are ongoing to generate more data on the safety and efficacy of remdesivir as a treatment for COVID-19. Remdesivir remains an investigational drug and has not been approved by USFDA.

  • 24 April 2020

    Jubilant Bhartia Group Contributes Rupees 10 Crore to PM Cares Fund

    Jubilant Bhartia Group, in a press statement, said that it has contributed Rupees 10 Crores to PM Cares fund to support Government of India’s initiatives in mitigating the COVID-19 crisis.

    Jubilant Bhartia Group, in a press statement, said that it has contributed Rupees 10 Crores to PM Cares fund to support Government of India’s initiatives in mitigating the COVID-19 crisis.

    Two group companies: Jubilant Foodworks Limited (one of the largest food service companies in India and master franchise of Domino’s Pizza and Dunkin' Donuts) and Jubilant Life Sciences Limited (an integrated global pharmaceuticals and life sciences company) contributed Rupees 5 Crores each to the fund. The contribution of Jubilant Life Sciences Limited, along with all its subsidiaries, includes one day gross salary of its 5300 employees.

    The Jubilant Bhartia Group companies are committed to support the Government, both central & states, in controlling the spread of the COVID-19 pandemic in the spirit of the Group’s promise of Caring, Sharing, Growing. Jubilant Bhartia Foundation (JBF), a not-for-profit organization of the Group, has taken several measures at the grassroots level in the areas of health & safety, food & ration distribution, sanitization, communication, medical & medicine, distribution of PPEs and support to the administration across various locations.

    JBF is distributing sanitizer manufactured by Jubilant Life Sciences Limited within the community, to healthcare workers and the Government at both central and state level. Food and medicine distribution (ready to eat food packets and dry ration) is also being undertaken to the vulnerable community members like migrant labourers, pregnant women, senior citizens, children at various places in the country. JBF is facilitating the stitching of reusable cotton masks at various sites in the country through Self Help Groups (SHGs). These masks are washable and reusable and the Foundation has been providing the raw material for them.

    Additionally, Jubilant FoodWorks Limited has been providing PPE kits and food distribution for the impacted citizens and Police staff. It has also leveraged its Domino’s delivery team and supply chain network for distribution of Essential commodities like flour, milk etc. to help citizens get their daily needs in the safety of their homes.

  • 16 April 2020

    Press Statement

    Jubilant Life Sciences Limited noted in a press statement today that no traces of COVID-19 virus have been found in the imported Raw Material sampled from Nanjangud facility of its subsidiary - Jubilant Generics Limited.

    Jubilant Life Sciences Limited noted in a press statement today that no traces of COVID-19 virus have been found in the imported Raw Material sampled from Nanjangud facility of its subsidiary - Jubilant Generics Limited. Raw Material (imported from China) tested negative for COVID-19 virus by National Institute of Virology, Pune as announced by the authorities of Government of Karnataka.

    It is unfortunate that a wrong perception was created in public and media about the Raw Material imported from China.

    Additionally, the Company clarified that Patient P52 did not travel to China or on any overseas trip in the last six months. Further, none of the employees tested positive so far travelled overseas in the last six months.

    Jubilant Generics Limited at its plant located at Nanjangud, Mysore manufactures Active Pharmaceutical Ingredients used in drugs that are needed for sustaining patients' lives, including Azithromycin Dihydrate and Azithromycin Monohydrate, which are needed to fight the global menace of COVID-19.

    All evidences and known scientific facts published by reputed global organisations, available so far, indicates that the virus does not survive for more than 72hours on any surface. The Raw Materials sampled from the Nanjangud facility had taken more than three weeks (>21days) of transit to reach the plant by Sea Route and no virus can survive this long on any surface.

    In any case, Patient P52, the first positive case of COVID-19 from the Nanjangud facility, never had any contact with any raw material nor had role in Receiving, Transporting, Handling or Storage of raw materials.

    Jubilant values the health and safety of employees and community in and around its facility. It is continuously working towards ensuring that all their needs are met and necessary precautionary measures as directed by Government protocols are being followed.

    The Company values the support it has received from all levels of Government authorities including District administration, Police, Public health department and the community around its facility. Jubilant is constantly communicating and working with them to mitigate the situation arising of the COVID-19.

  • 04 April 2020

    Jubilant Life Sciences supports distribution of health and safety material in Karnataka

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, said, that it is providing support to Government of Karnataka’s efforts in delivering effective health and safety services to manage COVID-19 crisis.

    Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, said, that it is providing support to Government of Karnataka’s efforts in delivering effective health and safety services to manage COVID-19 crisis.

    The Company spokesperson said, “At Jubilant Life Sciences we value the health and safety of our community and employees. We are continuously working towards ensuring that all their needs are met, taking necessary precautionary measures as well as following government directed protocols. We are also working closely with the district and state administration officials and are extending all necessary support for mitigating COVID-19 crisis.”

    The Company has distributed over 7,000 masks and around 325 litres of sanitizers to policy makers, health and administrative staff within the state of Karnataka. Furthermore, some of the daily wage workers are being supported through various networks to ensure access to food, masks and soaps. To draw awareness and help citizens understand the gravity of the situation, the Company has initiated educational drives across multiple locations, focusing on the importance of social distancing, sanitization and overall hygiene.

    As a precautionary measure, the Nanjangud plant operations have been temporarily suspended and all the personnel are under self-quarantine. The Company has proactively engaged an external certified agency for disinfection and has completed the disinfection process for all the plant areas to make the workplace safe and healthy.

    The Company has distributed over 5,000 masks, 200 litres of sanitizers, essential food items, water and medical facilities to employees and their extended families.

    Jubilant Life Sciences has contributed a sum of Rupees 25 lakhs towards the CM Relief Fund to support the Government’s efforts to combat the spread of COVID-19.

  • 26 March 2020

    Jubilant Life Sciences gives free hand sanitizers to support fight against COVID-19

    Jubilant Life Sciences Limited, a Jubilant Bhartia Group company, announced that its research and development team has developed formulation for hand sanitizer using its own produced Ethanol.

    Jubilant Life Sciences Limited, a Jubilant Bhartia Group company, announced that its research and development team has developed formulation for hand sanitizer using its own produced Ethanol. The company got necessary approvals & has quickly realigned its manufacturing facility to start producing hand sanitizers at a short notice. This was made possible due to support by   Government of Uttar Pradesh & its departments, who gave all the necessary approvals in record time, including Food Safety & Drug Administration, the Excise Department and the Uttar Pradesh Pollution Control Board.

    Jubilant Life Sciences has started supplying, free of cost, these hand sanitizers to Governments both at the national & the state level. Noida Administration, Government Hospital, Municipal, District Administration, Police Personnel at Jyotiba Phuley Nagar and Gautam Budha Nagar and the healthcare staff & volunteers working at All India Institute of Medical Sciences, Delhi have received the first instalment.

    Government of India has taken commendable actions against the spread of COVID-19. Jubilant Bhartia Group companies are committed to support these measures through the supply of hand sanitizers to the healthcare workers in the hospitals and in the field, to control the spread of this pandemic.